Antigout Agents
High-yield Verified · Oct 2026Prototype: allopurinol
Antigout Agents are a class of medications used for acute gout attack.
Gout drugs split into acute-attack relievers and long-term urate-lowerers — using the wrong one at the wrong time backfires.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 Gout — uric acid crystals in the joint
Gout happens when uric acid (the end-product of purine breakdown) builds up and forms sharp crystals in a joint — classically the big toe. The immune system attacks the crystals, causing a sudden, exquisitely painful, red, swollen joint (an acute gout attack). Over time, high uric acid also forms tophi and damages joints and kidneys.
That two-part disease needs two different drug strategies, and mixing them up is the classic error: calm the acute inflammation now, and lower uric acid for the long term — without stopping urate-lowering therapy when a flare hits.
02 Acute vs long-term — and the timing trap
For an acute attack, the goal is anti-inflammatory: colchicine (best early in the attack), NSAIDs, or corticosteroids (especially for flares in several joints, or when NSAIDs and colchicine are unsuitable, as in kidney impairment); IL-1 inhibitors (anakinra, canakinumab) are reserved for patients who can’t take or tolerate any of these. Colchicine works by disrupting the neutrophils that attack the crystals — but it has a narrow margin, causing dose-limiting diarrhea/GI toxicity and, in overdose or renal/hepatic impairment, serious toxicity.
For the long term, the goal is to lower uric acid: allopurinol and febuxostat block xanthine oxidase (the enzyme that makes uric acid), while probenecid helps the kidney excrete more urate. The crucial timing rules: do not stop a urate-lowering drug during a flare, and expect flares when it is started — changing uric-acid levels mobilize urate crystals, so colchicine or an NSAID is given as flare prophylaxis. Starting urate-lowering therapy during a flare is conditionally recommended if adequate anti-inflammatory therapy is given (2020 ACR guideline, as reported by StatPearls); probenecid’s label still says to wait until the attack has subsided.
03 Allopurinol’s serious risks
Allopurinol’s major danger is hypersensitivity — from rash up to Stevens-Johnson syndrome / toxic epidermal necrolysis and DRESS (higher risk with the HLA-B*58:01 allele). Any spreading rash means stop the drug. Allopurinol also dangerously raises levels of azathioprine and 6-mercaptopurine (both are metabolized by xanthine oxidase). Patients should push fluids to prevent urate stones, and understand that a flare can occur early in therapy — that isn’t a reason to stop.
Drug names
Indications
- Acute gout attack (colchicine, NSAIDs, corticosteroids; IL-1 inhibitors when these are unsuitable)
- Long-term urate lowering / chronic gout & tophi (allopurinol, febuxostat, probenecid)
- Tumor-lysis-syndrome prevention (allopurinol/rasburicase)
Mechanism of action
Acute agents are anti-inflammatory (colchicine inhibits neutrophil microtubules/migration; NSAIDs and steroids reduce inflammation). Urate-lowering agents reduce uric acid: allopurinol/febuxostat inhibit xanthine oxidase (↓ production); probenecid is uricosuric (↑ renal excretion).
Therapeutic effects — what you'll see working
Success is a settled acute attack and, long-term, a uric acid low enough to prevent recurrence and dissolve tophi (often target < 6 mg/dL). The timing rule — don’t stop urate-lowering therapy for a flare, and give flare prophylaxis when starting it — is a central nursing point.
- Acute attack relief
- Colchicine/NSAIDs/steroids reduce the crystal-driven inflammation, relieving the painful, swollen joint.
- Lowered uric acid (long-term)
- Xanthine-oxidase inhibitors or uricosurics keep uric acid low, preventing attacks and shrinking tophi over months.
Adverse effects
Colchicine’s issue is GI/narrow-margin toxicity; the urate-lowerers’ concern is triggering flares on initiation and (allopurinol) hypersensitivity/interactions.
Contraindications
The cautions are the timing rule, the allopurinol interactions/hypersensitivity, and colchicine in organ impairment.
When to hold
Assess before giving — these findings mean hold the dose and act.
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Common questions
What are Antigout Agents used for?
How do Antigout Agents work?
What are the serious side effects of Antigout Agents?
When should a nurse hold Antigout Agents, and what safety checks apply?
Conditions treated
This class does two entirely different jobs, and confusing them is the commonest error on the page. Urate-lowering therapy treats the DISEASE by removing the substrate. Colchicine treats or prevents the FLARE. Neither substitutes for the other. WHO STARTS URATE-LOWERING THERAPY — a STRONG ACR 2020 recommendation: "Initiating ULT is STRONGLY recommended for gout patients with ANY of the following: ≥ 1 SUBCUTANEOUS TOPHI; EVIDENCE OF RADIOGRAPHIC DAMAGE (ANY MODALITY) ATTRIBUTABLE TO GOUT; OR FREQUENT GOUT FLARES, WITH FREQUENT BEING DEFINED AS ≥ 2 ANNUALLY." It is conditionally recommended for patients with more than one flare but fewer than two a year, and conditionally recommended AGAINST after a first flare — "HOWEVER, initiating ULT is CONDITIONALLY RECOMMENDED for patients with comorbid MODERATE-TO-SEVERE CKD (STAGE ≥ 3), SU CONCENTRATION > 9 mg/dl, OR UROLITHIASIS." WHICH AGENT — STRONG: "we STRONGLY recommend ALLOPURINOL OVER ALL OTHER ULT AS THE PREFERRED FIRST-LINE AGENT FOR ALL PATIENTS, INCLUDING IN THOSE WITH CKD STAGE > 3," with a xanthine oxidase inhibitor strongly preferred over probenecid in that group, and pegloticase strongly recommended against as first-line. START LOW — STRONG: a low starting dose with titration to target; the guideline states 100 mg/day or less for allopurinol and lower in CKD, with 50 mg/day or less considered there, and under 40 mg/day for febuxostat (probenecid 500 mg once or twice daily is a conditional recommendation). The reason is explicit: "A LOWER STARTING DOSE OF ANY ULT REDUCES THE RISK OF FLARE ASSOCIATED WITH INITIATION," and the Patient Panel accepted "MORE BLOOD DRAWS AND PROVIDER VISITS" to get it. TREAT TO TARGET — STRONG, high certainty: titration "guided by SERIAL SU VALUES" over a fixed dose, "CONTINUING ULT TO ACHIEVE AND MAINTAIN AN SU TARGET OF < 6 mg/dl over no target," paced over "WEEKS TO MONTHS, NOT YEARS, to prevent TREATMENT INERTIA" — and note that ACR removed the extra thresholds its own 2012 guideline carried. Continuing indefinitely is conditional with very low certainty. FLARE PROPHYLAXIS WHEN STARTING — STRONG, twice: concomitant anti-inflammatory prophylaxis (colchicine, an NSAID, or prednisone/prednisolone) continued 3 to 6 months, because "SHORTER DURATIONS WERE ASSOCIATED WITH FLARES UPON CESSATION." TESTING — CONDITIONAL: HLA-B*5801 before allopurinol in patients of Southeast Asian descent (Han Chinese, Korean, Thai) and African American patients, because the allele carries "a MARKEDLY ELEVATED RISK for" allopurinol hypersensitivity syndrome; universal testing in other groups is conditionally recommended against. COLCHICINE FOR THE FLARE — STRONG: low-dose over high-dose "given its SIMILAR EFFICACY AND FEWER ADVERSE EFFECTS," following "FDA-approved dosing… (1.2 mg IMMEDIATELY FOLLOWED BY 0.6 mg AN HOUR LATER)." The class page owns each agent’s pharmacology and interactions.
Allopurinol for tumor lysis syndrome — "Treatment options include alkaline hydration, allopurinol, and rasburicase (a recombinant urate oxidase)."
"Allopurinol and febuxostat may be required in patients with significant hyperuricemia." NHS lists gout among PV symptoms.
Culprit — allopurinol. "Discontinue Allopurinol Tablets permanently at the first appearance of skin rash or other signs which may indicate a hypersensitivity reaction." Risk "is largely confined to the first few months of therapy"; consider HLA-B*58:01 screening where prevalence is high.
See also
Block cyclooxygenase to relieve pain, inflammation, and fever — at the price of GI bleeding, cardiovascular, and renal risk. They carry a two-part boxed warning.
Ease muscle spasm and spasticity — mostly by sedating the CNS. The defining risks are drowsiness/falls and additive depression with opioids, benzodiazepines, and alcohol.
Slow osteoclast bone breakdown to build bone density in osteoporosis. The exacting oral-administration protocol is central to nursing care — it protects the esophagus and rescues a <1% absorption.
Beyond the bisphosphonates, three kinds of drug treat bone and calcium. Teriparatide, abaloparatide and romosozumab build bone. Denosumab, raloxifene and calcitonin slow bone loss in other ways. Cinacalcet and calcitriol reset the calcium–parathyroid balance. Serum calcium runs through the nursing care of nearly all of them, and three carry boxed warnings: denosumab (Prolia) for severe hypocalcemia in advanced kidney disease, romosozumab for heart attack and stroke, and raloxifene for blood clots and death from stroke.
Sources
- Allopurinol — xanthine oxidase inhibition, SJS/TEN, azathioprine interaction — LiverTox (NCBI)
- Gout pharmacology — acute vs urate-lowering therapy, colchicine cautions — StatPearls (NCBI)
- Allopurinol Tablets — gout flares on initiation (do not discontinue), HLA-B*58:01, azathioprine/mercaptopurine dose reduction, fluids (FDA label) — FDA / DailyMed
- ULORIC (febuxostat) — boxed warning (cardiovascular death), azathioprine/mercaptopurine contraindication, flare prophylaxis (FDA label) — FDA / DailyMed
- MITIGARE (colchicine) — mechanism, contraindications with P-gp/CYP3A4 inhibitors, GI/myelosuppression/neuromuscular toxicity (FDA label) — FDA / DailyMed
- Probenecid Tablets — do not start until an acute attack subsides (FDA label) — FDA / DailyMed
- Allopurinol — xanthine oxidase, flares on initiation — StatPearls (NCBI)
- Febuxostat — non-purine xanthine oxidase inhibitor — StatPearls (NCBI)
- Colchicine — narrow therapeutic index, GI adverse effects, flare prophylaxis — StatPearls (NCBI)
- Tumor Lysis Syndrome — allopurinol or rasburicase prevention — StatPearls (NCBI)
- Colchicine tablets — contraindication with P-gp or strong CYP3A4 inhibitors in renal or hepatic impairment (FDA label) — FDA / DailyMed
- ALOPRIM (allopurinol sodium for injection) — cancer-therapy hyperuricemia (FDA label) — FDA / DailyMed
Reviewed by Hae Suk Lee, RN
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.